Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
This article was originally published in The Pink Sheet Daily
Executive SummaryAbbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.
You may also be interested in...
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.